Trial Condition(s):
Prospective, multicenter non interventional study to evaluate adherence to betaferon over a 2 years period (SEPLUS)
15098
Not Available
Not Available
The aim of the SEPLUS study is to evaluate the patients characteristics associated with adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in the BetaPlus program
- Male or female >/= 18 years old - Outpatient with a confirmed diagnosis of Recurrent-Remittent multiple sclerosis or patients at high risk of developing multiple sclerosis after a first demyelinating clinical event - Patient who initiated Betaferon as described by SmPC less than 2 months ago. The decision of physician is clearly separated from the decision to include the patient in the study - Treatment naïve patients before the initiation of Betaferon - OR Patients having interrupted Betaferon for more than 6 months before to start again - OR Patients receiving a disease modifying drug (DMD) other than Betaferon - Patient with EDSS score < 4 - Patients approved and signed an inform consent and approved the collect of their data
- Contraindications and warning of the respective Summary of Product Characteristics
Locations | |
---|---|
Locations Investigative Site Many Locations, France | Contact Us: E-mail: [email protected] Phone: Not Available |
Prospective multicenter, non interventional study to evaluate the patient's characteristics associated with adherence to treatment regimen by betaferon in the BetaPlus program
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1